PRAME antigen presented on HLA-A*02:01
Assets acting on this target.
- Class
- HLA-restricted, autologous TCR-engineered T cell therapy (TCR-T)
- Pathway
- MHC class I-restricted antigen recognition driving T cell-mediated tumor cytotoxicity
Related mechanisms